Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG101 plus reirradiation vs reirradiation in progressive glioblastoma
2009-013421-42Phase 2Completed
- Sponsor
- Apogenix
- Start
- Jul 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of asunercept in glioblastoma (GBM) (2 arms), sponsored by Apogenix. Primary endpoint: Progression-free survival at 6 months (PFS6). Started Jul 2009; status: completed.
02
Drugs
asunercept
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-013421-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013421-42.